SGS Increases Biosafety Testing Capacity at Glasgow Facility
SGS has just completed an expansion project at its Glasgow facility, meaning it can provide increased biosafety testing for the biologics, drug development, and cell and gene therapy industries.
The project, which began back in March 2021 and was completed in September 2021, saw the footprint of the Glasgow facility increase by 550m2, meaning the facility now totals 3,100m2 in size and has a staff of 130 employees.
Sixteen BSL-2 laboratories have been added to our Glasgow facility. These laboratories contain a range of equipment, including BSL-2 cabinets, ELISA (enzyme-linked immunosorbent assay) technology, cell culture equipment for virus detection and real-time PCR (polymerase chain reaction) testing equipment.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
